Barros LF, Schirmeier S, Weber B
Register Now Browse upcoming training dates and register for hands-on workshops in San Diego, CA
doi: 10.1016/j.ebiom.2016.12.012 143 ZadraGRibeiroCFChettaPHoYCacciatoreSGaoXet al
When tesamorelin is the more appropriate choice Tesamorelin is typically the preferred agent when: Visceral adipose tissue is the primary treatment target, particularly with associated metabolic comorbidities A clinician is working within a framework that prioritises FDA-approved agents The patient has HIV-associated lipodystrophy, the only approved indication A robust evidence base is required for clinical decision-making For general somatopause-related concerns gradual changes in body composition, sleep quality, and recovery the CJC-1295/ipamorelin combination remains more commonly used, primarily because of its flexible dosing profile and the preserved pulsatile GH release pattern
As a result, these tumors tend to be larger and less amenable to curative therapies than those with other etiologies7
231: 31522 Van Kempen TA, Odle J
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
